Wachtwoord vergeten?

Aandeel Kiadis Pharma AEX:KDS, NL0011323407

  • 5,270 27 nov 2020 17:35
  • +0,010 (+0,19%) Dagrange 5,260 - 5,275
  • 268.494 Gem. (3M) 848,4K

Lancering klinische fase nieuwe pijplijn nadert!

323 Posts
Pagina: «« 1 ... 5 6 7 8 9 ... 17 »» | Laatste | Omlaag ↓
  1. forum rang 6 Reply 6 maart 2020 09:00
    Volgende week 12 Maart dus het event:

    BioCapital Europe 2020 te Amsterdam

    Een bijeenkomt van o.a. grotere Biotech investeerders, zie onderstaand:

    "BioCapital Europe is Europe’s premier life sciences investment conference, offering VCs and Institutional Investors unique and timely access to around 40 exciting biotech, medtech and diagnostics companies from the Benelux and Europe. Attendance is by invitation only. In 2018, the event attracted over 250 attendees (mainly CEOs, CFOs, pharma execs, VCs, and Institutional Investors). VCs and Institutional Investors are invited to attend free of charge to this event."
  2. forum rang 6 Reply 6 maart 2020 14:38
    Events als "BioCapital Europe 2020" helpen de bekendheid van Kiadis bij de investeringsgemeenschap te vergroten.

    Aldus kunnen er ook nieuwe investeerders worden aangetrokken wat een koers ondersteunend of natuurlijk liefst koers verhogend effect kan hebben.
    Aankomend event is een belangrijke binnen met name de Europese biotech gemeenschap waar CEO Arthur Lahr een presentatie zal houden over het NK-Celtherapie platform en de brede inzetbaarheid ervan.

    En nieuwe investeerders zijn altijd welkom lijkt me!
  3. forum rang 6 Reply 10 maart 2020 09:32
    Kiadis Pharma announces new data on ex-vivo FC21 expanded NK-cell therapy in 13 patients with relapsed/refractory acute myeloid leukemia will be presented at the European Society for Blood and Marrow Transplantation Annual Meeting*

    Nieuwe data betreffende de werkzaamheid van Kiadis haar unieke NK-Celtherapie platform is altijd welkom!
  4. forum rang 4 Rotel74 10 maart 2020 09:33
    AMSTERDAM (AFN) - Nieuwe onderzoeksresultaten over een therapie van Kiadis Pharma zijn geaccepteerd voor een presentatie op een wetenschappelijk congres. Het gaat om onderzoek naar de werking van een door Kiadis ontwikkelde celtherapie tegen bepaalde vormen van leukemie.

    De resultaten van het Fase 1-onderzoek worden gepresenteerd op de jaarlijkse bijeenkomst van de European Society for Blood and Marrow Transplantation (EBMT) in Madrid, die eind augustus begint. Het in Brazilië uitgevoerde onderzoek draaide om de vraag of een therapie met cellen die bij het immuunsysteem horen, zogeheten NK-cellen, bijdraagt aan het verdere herstel van de hoeveelheid NK-cellen bij leukemiepatiënten. Onderzoekers keken daarbij ook of de therapie hielp bij het tegengaan van acute myeloïde leukemie.
  5. [verwijderd] 10 maart 2020 11:09
    Kiadis Pharma announces new data on ex-vivo FC21 expanded NK-cell therapy in 13 patients with relapsed/refractory acute myeloid leukemia will be presented at the European Society for Blood and Marrow Transplantation Annual Meeting*
    March 10, 2020
    EBMT Abstract #A-1137-0005-00784
    Amsterdam, The Netherlands, March 10, 2020 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, today announces an abstract showcasing the potential of the Company’s NK cell therapy to treat relapsed/refractory acute myeloid leukemia (R/R AML) has been accepted for an oral presentation at the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT). Lucia Mariano da Rocha Silla, MD, PhD, will present the data at EBMT, which is taking place 30 August – 2 September in Madrid, Spain. These data are from a Phase I study conducted by Dr. Silla at Hospital de Clínicas de Porto Alegre (HCPA) in Brazil. In this study, sponsored by the Brazilian Agencies for Research development, the adoptive transfer of haploidentical expanded NK cells to restore NK cell numbers and anti-leukemia function in patients with relapsed/refractory AML was investigated.
    Presentation Details
    Title: Phase 1 Study of Adoptive Transfer of Haploidentical Expanded NK Cells
    Presenter: Lucia Mariano da Rocha Silla, MD, PhD
    Abstract #: #A-1137-0005-00784 ( Session Name: OS6 session 6 - Cellular therapy other than CARs
    *EBMT has postponed its 46th Annual Meeting from March 2020 to 30 August to 2 September 2020.
    Kiadis Pharma Contact
    Maryann Cimino, Manager, Corporate Affairs Tel: +1 (617) 710-7305
    About Kiadis Pharma’s K-NK-Cell Therapies
    Kiadis Pharma’s NK-cell programs consist of off-the-shelf and haplo donor cell therapy products for the treatment of liquid and solid tumors as adjunctive and stand-alone therapies.
    The Company’s NK-cell PM21 particle technology enables improved ex vivo expansion and activation of anti-cancer cytotoxic NK-cells supporting multiple high-dose infusions. Kiadis Pharma’s proprietary off-the-shelf NK-cell platform is based on NK-cells from unique universal donors. The Kiadis Pharma off-the-shelf K-NK platform can make NK-cell therapy product rapidly and economically available for a broad patient population across a potentially wide range of indications.
    Kiadis Pharma is clinically developing K-NK003 for the treatment of relapse/refractory acute myeloid leukemia. The Company is also developing K-NK002, which is administered as an adjunctive immunotherapeutic on top of HSCT and provides functional, mature and potent NK-cells from a haploidentical family member. In addition, the Company has pre-clinical programs evaluating NK-cell therapy for the treatment of solid tumors.
    About Kiadis Pharma
    Founded in 1997, Kiadis Pharma is building a fully integrated biopharmaceutical company committed to developing innovative therapies for patients with life-threatening diseases. With headquarters in Amsterdam, the Netherlands, and offices and activities across the United States, Kiadis Pharma is reimagining medicine by leveraging the natural strengths of humanity and our collective immune system to source the best cells for life.
    Kiadis Pharma is listed on the regulated market of Euronext Amsterdam and Euronext Brussels since July 2, 2015, under the symbol KDS. Learn more at
    Forward Looking Statements
    Certain statements, beliefs and opinions in this press release are forward-looking, which reflect Kiadis Pharma or, as appropriate, Kiadis Pharma officers’ current expectations and projections about future events. By their nature, forward-looking statements involve a number of known and unknown risks, uncertainties and assumptions that could cause actual results, performance, achievements or events to differ materially from those expressed, anticipated or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, regulation, competition and technology, can cause actual events, performance, achievements or results to differ significantly from any anticipated or implied development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, Kiadis Pharma expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or projections, or any change in

    events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither Kiadis Pharma nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the anticipated or implied developments. You should not place undue reliance on forward- looking statements, which speak only as of the date of this press release.
  6. forum rang 6 Reply 10 maart 2020 13:05
    Gezien de overtuigende nieuwe data hoop ik dat ook de Amerikaanse investeerders nog wakker zullen worden:

    Results: NK cell production was feasible for all subjects. 13 patients were treated (one treated twice), age 1-61y (median 22y), with primary refractory (n= 5) or relapsed (n=8) AML. Patients had a median of five prior therapies, including nine with prior stem cell transplantation. Two patients had CNS, one bone and nerve root disease and one CNS probable mycetoma. Therapy was tolerated with manageable toxicity in such an ill population of patients. Median neutrophil and platelet recovery were at day 33 and 44, respectively. Complete response and overall response rate were 50% and 78.5%, respectively, including unexpected CNS responses that were associated with localized inflammation. Median OS and DFS after treatment were 271 and 90 days, respectively.

    Conclusions: Repeated infusions of high doses of cryopreserved expanded NK cells are feasible and well-tolerated after high-dose chemotherapy and demonstrate encouraging systemic and CNS responses in high-risk AML.
  7. forum rang 6 Reply 10 maart 2020 15:44
    In de afgelopen twee weken heeft Kiadis nu een paar uitstekende persberichten uitgegeven welke werden ontvangen in een dramatisch beursklimaat.
    Hoe anders zou de koers reeds zijn geweest bij positievere marktomstandigheden.
    En nogmaals, de feitelijke reden van de huidige marktomstandigheden doen niets af aan de voortgang in de pijplijn bij Kiadis waarvan de onderzoeken gewoon doorlopen en/of worden voorbereid.
    Bij een verder beursherstel verwacht ik Kiadis dan ook bij de potentiële koplopers in koersherstel. De potentie van goedkeuring door de FDA op 26 Februari voor gebruik in verdere klinische studies van het NK-Celtherapie platform alsook het signaal welke uitgaat van de vandaag op 10 Maart aangekondigde en overtuigende nieuwe onderzoeksdata is nu nog geheel niet in de koers verwerkt.
323 Posts
Pagina: «« 1 ... 5 6 7 8 9 ... 17 »» | Laatste |Omhoog ↑

Plaats een reactie

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord

Direct naar Forum

Kiadis Pharma Meer »

Koers 5,270   Verschil +0,01 (+0,19%)
Laag 5,260   Volume 268.494
Hoog 5,275   Gem. Volume 848.394
27 nov 2020 17:35
label premium

Kiadis: Knock-out bod van Sanofi (Update)

Het laatste advies leest u als IEX Premium-lid

Inloggen Ontdek Premium
Quotedata: Amsterdam realtime by Euronext, other realtime by Cboe Europe Ltd.   US stocks: by NYSE & Cboe BZX Exchange, 15min delayed
#/^ Index indications calculated real time, zie disclaimer, streaming powered by Infront. Crypto data by Crypto Compare